Related Experiment Video
Updated: May 30, 2026
04:16
Inspiratory Muscle Training as an Adjunct to the Treatment of Weaning Failure in Critically Ill Patients: A Practical Guide
Published on: January 30, 2026
Weaning infants with phenylketonuria: a review
A MacDonald1, S Evans, B Cochrane
1Dietetic Department, Birmingham Children's Hospital, Steelhouse Lane, Birmingham, UK. anita.macdonald@bch.nhs.uk
Summary
Weaning infants with phenylketonuria (PKU) requires careful management of phenylalanine intake. Current practices lack evidence-based guidelines, highlighting the need for further research into optimal infant nutrition and diet therapy.
Area of Science:
- Metabolic disorders
- Pediatric nutrition
- Dietary therapy
Background:
- Phenylketonuria (PKU) necessitates strict dietary phenylalanine restriction.
- Current weaning guidelines for PKU infants are lacking evidence.
- Existing practices prioritize metabolic control over social aspects of weaning.
Purpose of the Study:
- To critically review existing literature on weaning in PKU.
- To examine current UK weaning practices for infants with PKU.
- To identify gaps and suggest future research directions for evidence-based guidelines.
Main Methods:
- Literature review of PKU weaning practices.
- Analysis of current UK weaning approaches for PKU infants.
- Critical examination of dietary management strategies.
Main Results:
- Weaning in PKU involves gradual introduction of low-protein solids and phenylalanine exchanges.
- Early introduction of solids (before 6 months) may improve food acceptance.
- Protein substitute intake requires careful management to balance nutritional needs and appetite.
Conclusions:
- Evidence-based weaning guidelines for PKU are needed.
- Further research should investigate factors influencing PKU infant weaning and protein substitute efficacy.
- Optimizing weaning practices can improve nutritional outcomes and quality of life for PKU infants.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:21Overview of Protein Metabolism
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...